Search Results
Your search for The ASCO ,The ASCO matches 21460 pages
Showing 18951 - 190002015 Oncology Meetings
FEBRUARY AACR-SNMMI Joint Conference: State-of-the-Art Molecular Imaging in Cancer Biology and TherapyFebruary 11-14 • San Diego, California For more information: www.aacr.org 2015 BMT Tandem Meeting American Society for Blood and Marrow TransplantationFebruary 11 - 15 • San Diego, California For...
Suzanne Topalian, MD, Recognized for Pioneering Work in Immunotherapy Treatment of Melanoma and Other Cancers
The Melanoma Research Alliance has reported that Suzanne Topalian, MD, Chair of the group’s Scientific Advisory Panel, and former Chief Scientific Officer, has been named one of 10 people in science who mattered in 2014 by the Nature International Weekly Journal of Science. Dr. Topalian was cited...
West Cancer Center Announces The University of Tennessee/West Institute for Cancer Research
West Cancer Center has announced the establishment of The University of Tennessee (UT)/West Institute for Cancer Research, a nonprofit public charity fully dedicated to raising funds for adult cancer research in Memphis. The UT/West Institute for Cancer Research is soliciting grants from government ...
Friends of Cancer Research Holds Annual Conference on Clinical Cancer Research
Friends of Cancer Research, in conjunction with the Engelberg Center for Health Care Reform at Brookings, recently held the seventh annual Conference on Clinical Cancer Research in Washington, DC. The panels that comprised the daylong meeting discussed a future that has already begun. The most...
Transitioning From Volume to Value in Cancer Care
In an oncology health-care system that is increasingly changing its delivery and payment models, how do busy oncologists successfully bridge the transition from a volume- to value-based, patient-centric model? This, and other topics on value fueled a robust discussion at the Association of...
Supplemental New Drug Application for Carfilzomib
Amgen and its subsidiary Onyx Pharmaceuticals, Inc, announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) carfilzomib (Kyprolis) to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least...
CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine:daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the Fast...
New Choosing Wisely List, Leukemia Quick-Takes From ASH
Nearly 5,000 scientific abstracts were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exhibition in San Francisco. Along with our targeted coverage of the meeting’s key newsmakers, The ASCO Post provides you with these brief reports of other interesting...
Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer
Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature...
Expert Point of View: Matthew J. Ellis, MB, BChir, PhD
Matthew J. Ellis, MB, BChir, PhD, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, commented on endocrine resistance and the potential of the four-gene panel for assessing resistance for The ASCO Post. Endocrine response and resistance is a research focus...
ASCO Policy Statement Urges Removal of Barriers to Patient Participation in Phase I Clinical Trials
ASCO has released a policy statement calling for greater access to and education about phase I clinical trials, the first-in-human studies of new agents designed to fight cancer. In “The Critical Role of Phase I Trials in Cancer Research and Treatment” ASCO policy statement, the Society stresses...
Help Your Patients Understand the Importance of Phase I Clinical Trials
Encourage your patients to consider participating in clinical trials, including phase I clinical trials. Direct your patients to www.cancer.net/clinicaltrials for detailed information about the purpose and advantages of clinical trials and why today’s phase I studies are different. On the...
ASCO Names Advance of the Year, Reviews Top Research Trends
In just a year’s time, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), treatments that are highly effective and far easier for patients to tolerate. These therapies are a major step forward, bringing renewed hope to nearly 120,000 people living with CLL...
Five Organizations Awarded 2015 International Innovation Grants to Improve Cancer Care in Low- and Middle-Income Countries
The Conquer Cancer Foundation of ASCO has announced the five recipients of the 2015 International Innovation Grant. This grant supports novel and innovative projects that may improve diagnosis, prevention, and treatment of cancer in low- and middle-income countries. For 2015, the 1-year grants of...
Cornerstone Spotlight: Frank M. Muller, Jr
Frank M. Muller, Jr, the newest member of the Conquer Cancer Foundation (CCF) Cornerstone Planned Giving Society, has a 40-year history of successfully leading investment and high-tech corporations. He served 8 years on active duty in tours to Vietnam. It is rare for him to experience a challenge...
Molecular Classification Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
Radical cystectomy is the standard therapeutic option for patients with muscle-invasive bladder cancer. However, 5-year overall survival for high-risk patients with pT3, pT4, pN-negative, and pN-positive M0 bladder cancer after radical cystectomy is only about 50% and ranges from 32% in patients...
University of Pittsburgh Appoints Director of Stem Cell Transplantation
Warren Shlomchik, MD, has been named Director of Stem Cell Transplantation and Cell Therapies for the University of Pittsburgh’s Division of Hematology-Oncology and the University of Pittsburgh Cancer Institute (UPCI). His appointment is effective March 1, 2015. He also will serve as UPCI’s...
Treating Bladder Cancer in 2015
Treatment of advanced bladder cancer continues to prove challenging, and therapies that offer long-term survival remain elusive. The ASCO Post recently spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, President of the Levine Cancer Center, Charlotte, North Carolina, about the current state...
FDA Appoints Robert Califf, MD, Deputy Commissioner for Medical Products and Tobacco
U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, MD, has appointed Robert Califf, MD, as the FDA Deputy Commissioner for Medical Products and Tobacco. Dr. Califf is a leader in cardiology, clinical research, and medical economics, who is currently serving as Vice...
FDA Expands Approved Use of Ibrutinib for Waldenström’s Macroglobulinemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for patients with Waldenström’s macroglobulinemia, a rare, indolent type of B-cell lymphoma. Ibrutinib is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously...
Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy: A Winner in Older Patients With Leukemia
Inotuzumab ozogamicin combined with a low-intensity chemotherapy called mini-hyper-CVD achieved highly encouraging results in older patients with acute lymphoblastic leukemia (ALL) in a phase II study reported at the 56th Annual Meeting of the American Society of Hematology.1 After the...
Expert Point of View: Ann H. Partridge, MD, MPH
Ann H. Partridge, MD, MPH, Associate Professor of Medicine at Harvard Medical School, commented on this study to The ASCO Post: With taxanes after doxorubicin/cyclophosphamide (AC), it’s “dealer’s choice.” However, she noted that most oncologists do not give every-3-week paclitaxel now. “Many have...
ASCO Releases Annual Report on Progress Against Cancer
ASCO recently released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). The report credited improvements in CLL care with four...
Cancer Genetics: Looking Back, Looking Ahead
At the 2014 San Antonio Breast Cancer Symposium, The ASCO Post sat down with geneticist Mary-Claire King, PhD, for some personal musings about her career and how she might guide young researchers who want to follow in her footsteps. Dr. King is known for a variety of accomplishments in genetics,...
Expert Point of View: George J. Chang, MD
George J. Chang, MD, Chief of Colon and Rectal Surgery and Director of Clinical Operations, Minimally Invasive and New Technologies in Oncologic Surgery Program at The University of Texas MD Anderson Cancer Center, Houston, shared his insights on the study by Dr. Smith and colleagues with The ASCO...
Dr. Howard Fine Named Founding Director of the Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and...
Glioblastoma Clinical Trials
I am writing in regard to the recent installment to “Clinical Trials” on Glioblastoma published in The ASCO Post (February 10, 2015, pages 69-71). As a principal investigator, I’d also like to call attention to the following glioblastoma trial, which remains open. PHASE II Study Type: Phase...
More on Beating the Odds
Thank you very much for including Mr. Richard Heimler’s very rewarding story in The ASCO Post (“Beating the Odds,” December 1, 2014, page 118). It was a short, well-written example of excellent oncology management in the face of episodes of “terminal” lung cancer. His story was the perfect...
ASCO to Launch Journal of Global Oncology, Names Founding Editor-in-Chief
ASCO has announced the appointment of David Kerr, MD, DSc, as founding Editor-in-Chief of the Society’s new Journal of Global Oncology (JGO). Dr. Kerr will set the editorial scope and vision for JGO, an online-only, open-access journal, which will focus on cancer care, research, and care-delivery...
Expect Questions About Atypical Hyperplasia as an Important Risk Factor for Breast Cancer
A special report in The New England Journal of Medicine concluded that atypical hyperplasia of the breast “confers an absolute risk of later breast cancer of 30% at 25 years of follow-up.1” This is higher than previously recognized, and the report’s authors urged “more intensive screening and...
Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening
Atypical hyperplasia of the breast has “special importance as a predictor of future breast cancer,” according to a special report in The New England Journal of Medicine.1 That special importance is based on the high incidence of atypical hyperplasia—found in around 10% of the 1 million breast...
Physician-Scientist Guido Marcucci, MD, Joins City of Hope
Renowned physician and researcher Guido Marcucci, MD, has joined City of Hope in a key leadership role within the institution’s new Hematologic Malignancies and Stem Cell Transplantation Institute. As Director of the Gehr Family Center for Leukemia Research and as Chief of the Division of...
Thomas J. Smith, MD, Honored by the American Cancer Society
Thomas J. Smith, MD, has been selected by the American Cancer Society to be the recipient of the 2015 Trish Greene Quality of Life Award. This award honors the life and work of the late Patricia (Trish) Greene, RN, PhD. As progress in the detection and treatment of cancer prolonged lives and...
Roswell Park Cancer Institute Announces Candace S. Johnson, PhD, as 15th President and Chief Executive Officer
The Roswell Park Cancer Institute (RPCI) Board of Directors has named Candace S. Johnson, PhD, as the Institute’s 15th President and Chief Executive Officer (CEO). Dr. Johnson will be the first female leader for this 117-year-old comprehensive cancer center. “Over the past few months, we have met...
NCI-Funded Program on Screening for Psychosocial Distress Accepting Applications
Funded by a grant from the National Cancer Institute (NCI), the Screening for Psychosocial Distress Program is a joint project of Yale University School of Nursing and the American Psychosocial Oncology Society (APOS). The Screening for Psychosocial Distress Program trains cancer care providers on...
Susan M. O’Brien Joins UC Irvine/Chao Family Comprehensive Cancer Center
Susan M. O’Brien, MD has joined UC Irvine Health as Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research. A renowned researcher and clinician, Dr. O’Brien’s leadership...
2015 Oncology Meetings
FEBRUARY Genitourinary Cancers SymposiumFebruary 26-28 • Orlando, Florida For more information: www.gucasym.org 5th Annual Texas Adolescent and Young Adult Oncology ConferenceFebruary 27-28 • Houston, Texas For more information:...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Skull Sarcoma Removed Under Local Anesthesia, East Prussia, Circa 1921
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Radium Era: 1916–1945.” To view additional photos from this series...
At Long Last: CMS Will Cover Lung Cancer Screening
Few issues in health-care debates are more contentious and polarizing than population screening for the early detection of cancer. After a decades-long battle, lung cancer screening advocates have just received what they have long sought: The Centers for Medicare & Medicaid Services (CMS) has...
ASTRO Announces Additions to Management Team
The American Society for Radiation Oncology’s (ASTRO) Board of Directors has announced three additions to the Society’s management team: Emily Wilson has been named Executive Vice President; Dave Adler has been promoted to Vice President of Advocacy; and Anne Hubbard has been promoted to Director...
Capsaicin
Scientific name: 8-methyl-N-vanillyl-6-nonenamide Brand names: Zostrix cream 0.025% or 0.075%, Salonpas Gel-Patch Hot, Sinus Buster (homeopathic intranasal spray). The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence ...
Blinatumomab in Philadelphia Chromosome–Negative Relapsed/Refractory B-Cell Precursor ALL
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 3, 2014, blinatumomab (Blincyto) was granted...
Iniparib: The Fairy Tale Dream Comes to an End
The first poly ADP ribose polymerase (PARP) inhibitor was developed in the early 1990s. Since then, the activity of PARP inhibitors has been explored in a variety of settings, including and perhaps most enthusiastically in the treatment of cancer. The greater dependence of several cancers on PARP,...
Ibrutinib for Waldenström’s Macroglobulinemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 29, 2015, the U.S. Food and Drug Administration (FDA)...
Case Reports on Myeloid Neoplasm
Case 1: Prerequisites for classification of myeloid neoplasm Question 1: Which statement is the one best explanation for the discrepancy observed between the blast percentage by bone marrow aspirate visual inspection and the flow-cytometry study? Correct Answer: C. Flow-cytometry study may not be...
Two Case Reports on the Evaluation of Myeloid Neoplasm
The ASCO Post is pleased to introduce “Hematology Expert Review,” a new feature including a case report detailing a particular hematologic condition followed by questions. Answers to each question appear with expert commentary. In this first installment, we present two cases of older men with...
IOM Report Recommends Guidelines for Sharing Clinical Trial Data
A new report from the Institute of Medicine (IOM) provides recommended guidelines about what data should be shared at key times in a clinical trial. In its report, Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk, an IOM committee concludes that sharing data is in the public...
Show Your Patients the Latest Research on Genitourinary Cancers
The 2015 Genitourinary Cancers Symposium takes place February 26 to 28 in Orlando, Florida. Direct your patients to www.cancer.net/blog to read about the latest research on prostate, bladder, kidney, testicular, and other genitourinary cancers being presented at the meeting. ■ © 2015. American...
Health-Care Issues Front and Center on Capitol Hill, in Statehouses This Year
As of January 6, Republicans hold the majority in both houses of the 114th Congress. They hold 54 seats in the U.S. Senate and 245 seats in the U.S. House of Representatives. At the state level, Republicans now hold an increased majority of governorships and legislatures that will consider numerous ...
